Literature DB >> 16039869

Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy.

Anna L Taylor1, Christopher J E Watson, J Andrew Bradley.   

Abstract

Effective immunosuppression is an essential pre-requisite for successful organ transplantation and improvements in outcome after transplantation have to a large extent been dependent on developments in immunosuppressive therapy. Here we provide an overview of the different immunosuppressive agents currently used in solid organ transplantation. A historical perspective on the development of immunosuppression for organ transplantation is followed by a review of the individual agents, with a focus on their mechanism of action and efficacy. Steroids, anti-proliferative agents (azathioprine and mycophenolate), calcineurin inhibitors (cyclosporine and tacrolimus) and TOR inhibitors (sirolimus and everolimus) are discussed along with both polyclonal and monoclonal antibody preparations. Many of the key clinical trials that underpin current clinical usage of these agents are described and side-effects of the different agents are highlighted. Finally, a number of newer agents still in various stages of clinical development are briefly considered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039869     DOI: 10.1016/j.critrevonc.2005.03.012

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  94 in total

1.  Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction.

Authors:  Itziar Oteo; John C Lukas; Nerea Leal; Elena Suarez; Andres Valdivieso; Mikel Gastaca; Jorge Ortiz de Urbina; Rosario Calvo
Journal:  Eur J Clin Pharmacol       Date:  2012-06-03       Impact factor: 2.953

2.  Rapamycin Prolongs Graft Survival and Induces CD4+IFN-γ+IL-10+ Regulatory Type 1 Cells in Old Recipient Mice.

Authors:  Markus Quante; Timm Heinbokel; Karoline Edtinger; Koichiro Minami; Hirofumi Uehara; Yeqi Nian; Haruhito Azuma; Reza Abdi; Abdallah Elkhal; Stefan G Tullius
Journal:  Transplantation       Date:  2018-01       Impact factor: 4.939

3.  Adoptive T cell therapy for the treatment of viral infections.

Authors:  Reuben J Arasaratnam; Ann M Leen
Journal:  Ann Transl Med       Date:  2015-10

4.  Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis.

Authors:  Kevin Zarca; Isabelle Durand-Zaleski; Marie-Anne Loriot; Gilles Chatellier; Nicolas Pallet
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

5.  Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling.

Authors:  Christina D Keller; Pilar Rivera Gil; Markus Tölle; Markus van der Giet; Jerold Chun; Heinfried H Radeke; Monika Schäfer-Korting; Burkhard Kleuser
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

6.  Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.

Authors:  Ji H Choi; Yoon J Lee; Seong B Jang; Jong-Eun Lee; Kyung H Kim; Kyungsoo Park
Journal:  Br J Clin Pharmacol       Date:  2007-03-28       Impact factor: 4.335

Review 7.  T-regulatory cell-mediated immune tolerance as a potential immunotherapeutic strategy to facilitate graft survival.

Authors:  Mohammad A Khan; Sana Moeez; Suhail Akhtar
Journal:  Blood Transfus       Date:  2013-05-07       Impact factor: 3.443

Review 8.  Overview of immunosuppression in liver transplantation.

Authors:  Anjana A Pillai; Josh Levitsky
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

9.  Inositol 1,4,5-trisphosphate receptor type 3 plays a protective role in hepatocytes during hepatic ischemia-reperfusion injury.

Authors:  Antônio Carlos Melo Lima Filho; Andressa França; Rodrigo M Florentino; Marcone Loiola Dos Santos; Fernanda de Oliveira Lemos; Dabny Goulart Missiaggia; Roberta Cristelli Fonseca; André Gustavo Oliveira; Meenakshisundaram Ananthanarayanan; Mateus T Guerra; Matheus de Castro Fonseca; Paula Vieira Teixeira Vidigal; Cristiano Xavier Lima; Michael H Nathanson; M Fatima Leite
Journal:  Cell Calcium       Date:  2020-08-11       Impact factor: 6.817

10.  Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosuppressive drugs.

Authors:  Brian C Wulff; Jennifer M Thomas-Ahner; Jonathan S Schick; Tatiana M Oberyszyn
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.